Released Nov 6, 2014, after the close
10-Q filed Nov 6, 2014, 37 days after period end · 0001171843-14-005331
Q3 2014 · 10-Q
Revenue$25.45M$25.45M +1.2% vs Q3 2013−5.6% vs Q2 2014
Net Income$633.00K$633.00K N/M vs Q3 2013−38.1% vs Q2 2014
EPS Diluted$0.02$0.02 N/M vs Q3 2013−33.3% vs Q2 2014
Gross Profit$11,442,000+1.3%
Operating Income$1,425,000+244.2%
Operating Cash Flowderived$602,000−57.9%
Margins · derived
Gross margin45.0%+0.0 pt vs Q3 2013
Operating margin5.6%+4.0 pt vs Q3 2013
Net margin2.5%+6.4 pt vs Q3 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2014 | Q3 2013 | Q3 2012 | Q3 2011 |
|---|---|---|---|---|
| Revenue | $25.45M | $25.14M | $26.10M | $26.38M |
| Net Income | $633.00K | -$984.00K | -$133.00K | $28.00K |
| EPS Diluted | $0.02 | -$0.03 | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR